Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Trénaunay syndrome

Blood Coagul Fibrinolysis. 2013 Oct;24(7):766-70. doi: 10.1097/MBC.0b013e3283626238.

Abstract

Klippel-Trénaunay syndrome (KTS) is a rare congenital anomaly characterized by malformation of lymph and blood vessels as well as growth disturbance of soft tissue and bone. The clinical picture is variable and associated with an increased risk of thromboembolic events mediated by intravascular coagulopathy in venous malformations. Here, we report on a male patient with KTS suffering from recurrent deep vein thrombosis (DVT) and life-threatening bleeding due to consumptive coagulopathy. Furthermore, we describe the successful long-term anticoagulant management with rivaroxaban.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anticoagulants / administration & dosage*
  • Disseminated Intravascular Coagulation / drug therapy*
  • Disseminated Intravascular Coagulation / etiology
  • Factor Xa / administration & dosage*
  • Humans
  • Klippel-Trenaunay-Weber Syndrome / complications*
  • Male
  • Morpholines / administration & dosage*
  • Rivaroxaban
  • Thiophenes / administration & dosage*

Substances

  • Anticoagulants
  • Morpholines
  • Thiophenes
  • Rivaroxaban
  • Factor Xa